What's breaking now, across thousands of outlets.
After tinkering with the biology of the broadly appealing anti-inflammatory NLRP3 pathway, NodThera is now plotting its pivotal trial plans for 2027. The decade-old biotech said Wednesday it is rebranding to Rezera ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Pfizer and Merck KGaA's venture groups are backing a nimble cancer startup taking a different approach to the popular antibody-drug conjugate and radioligand fields.
Kura Oncology, the maker of the leukemia menin inhibitor Komzifti, is spinning out its diabetes R&D to a new company that has attracted the attention of the leading pharma in the metabolic ...
The business of advancing shelved pharma assets continues to reap benefits, this time for Beeline Medicines and a lupus candidate provided by Bristol Myers Squibb.
Bangladesh has been racing to halt the measles outbreak spread since March, when more than 100 children died in less than a month.
A majority of Kenyans who said they were aware of an Ebola treatment centre in Laikipia/Nanyuki opposed its establishment, according to a new poll by research firm TIFA.
A join is how you ask one question across two tables. The database keeps patients in one table and appointments in another, because storing the patient's name on every appointment row would mean…
